A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

NCT01567163 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumor

Interventions

BIOLOGICAL: Ramucirumab
DRUG: Docetaxel

Sponsor

Eli Lilly and Company